Downregulation of Serum miR-133b and miR-206 Associate with Clinical Outcomes of Progression as Monitoring Biomarkers for Metastasis Colorectal Cancer Patients.

Surasak Wanram Namphon KlaewklaParichart Pinyosri

Published in: MicroRNA (Shariqah, United Arab Emirates) (2024)

The circulating serum miR-133b and miR-206 can serve as significant biomarkers for monitoring the clinical outcome of progression with metastatic CRC patients. Increased drug-responsive CRC patients associated with crucial molecular intervention should be further explored, clinically.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
cell proliferation
small cell lung cancer
prognostic factors
patient reported outcomes
cancer therapy